X hits on this document

Word document

SAINT-PETERSBURG – 2010 - page 57 / 128

343 views

0 shares

0 downloads

0 comments

57 / 128

moderate, or severe BA. PASP in Group I (28.1±0.7 mmHg) was slightly lower as compared with patients from Group II (31.2±0.9 mmHg, p<0.05), Group III (31.1±0.8 mmHg, p<0.01), Group IV (31.2±0.8 mmHg, p<0.01). After treatment was completed no significant decrease in PASP was found.

When we measured serum ET-1 levels we did not reveal significant differences between whole group of patients with BA (first and second examination) and control group (Table 2).

Table 2

ET-1 serum level in examined patients, fmol/ml

Groups of patients

Before treatment

After treatment

BA, n=80

0.232±0.022

0.242±0.020

Control group, n=10

0.208±0.025

ET-1 serum level was not significantly different among patients with mild, moderate or severe BA (Table 3).

Table 3

ET-1 serum level in examined patients according to

the BA severity level, fmol/ml

Groups of patients

Before treatment

After treatment

mBA, n=5

0.177±0.034

0.216±0.037

moBA, n=56

0.247±0.031

0.252±0.025

sBA, n=19

0.202±0.019

0.223±0.047

Control group, n=10

0.208±0.025

We found out that ET-1 serum level was significantly affected with associated cardiovascular pathology (Table 4). After treatment there was shown that patients from Group III and Group I had significant differences in ET-1 serum levels (0.315±0.053 vs. 0.207±0.027 fmol/ml, respectively, p<0.05).

After treatment patients in Group III had higher ET-1 level in serum than before treatment (0.315±0.053 vs. 0.196±0.022 fmol/ml, respectively, p<0.05).

Table 4

ET-1 serum level in BA patients according to concomitant EH, fmol/ml

Document info
Document views343
Page views343
Page last viewedThu Dec 08 10:31:34 UTC 2016
Pages128
Paragraphs1794
Words33610

Comments